BioMarin Pharmaceutical Inc. diskutieren

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $115.00. They now have an "overweight" rating on the stock.

BioMarin Pharmaceutical is a promising biotech stock that has caught my attention lately. The recent news about the positive results from the investigator-led 5-year study on their drug VOXZOGO, which showed a significant increase in bone length for children with achondroplasia, is particularly encouraging. This could be a game-changer for the company and open up new market opportunities. Additionally, the options market seems to be predicting a potential spike in the stock price, which is always an intriguing signal for investors. While the current share price of $78.78 may seem a bit high, I believe the long-term growth potential of BioMarin's pipeline and the positive momentum surrounding their key products make this stock a compelling buy. I'm optimistic about the company's future and think it's worth adding to my portfolio, with a target price of $95 per share.